![Nature Medicine på Twitter: "Toni Ribas @UCLA will next talk at #KSCancerImm about novel immune #checkpointblockade combos. He recently showed that treatment with anti-PD-1 or anti-PD-L1 agents produces a high response rate Nature Medicine på Twitter: "Toni Ribas @UCLA will next talk at #KSCancerImm about novel immune #checkpointblockade combos. He recently showed that treatment with anti-PD-1 or anti-PD-L1 agents produces a high response rate](https://pbs.twimg.com/media/D1jOzbXX4AEcBoM.png)
Nature Medicine på Twitter: "Toni Ribas @UCLA will next talk at #KSCancerImm about novel immune #checkpointblockade combos. He recently showed that treatment with anti-PD-1 or anti-PD-L1 agents produces a high response rate
![Nature Medicine on Twitter: "A new study estimates that the overall symptomatic case fatality risk - the probability of dying after developing symptoms of #COVID19 in Wuhan - was about 1.4%. Read Nature Medicine on Twitter: "A new study estimates that the overall symptomatic case fatality risk - the probability of dying after developing symptoms of #COVID19 in Wuhan - was about 1.4%. Read](https://pbs.twimg.com/media/ETdnCczWAAAmRJk.jpg)
Nature Medicine on Twitter: "A new study estimates that the overall symptomatic case fatality risk - the probability of dying after developing symptoms of #COVID19 in Wuhan - was about 1.4%. Read
Nature - A Nature Medicine paper presents a risk calculator calibrated for the US that provides estimates of risk for COVID-19 for individuals and at the community level. Read the paper: https://go.nature.com/3gEaXnO
![Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study | Nature Medicine Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-019-0407-5/MediaObjects/41591_2019_407_Fig1_HTML.png)